8/11/2019 Eurofins Fact Sheet August 2013

1/1

File Name: Eurofins Fact Sheet August 2013.doc EDR: 1-C-IR-EXE-01171823 Last modified on: 27/08/2013 Last modified by: Sylvain Besson Page 1 of 1

Our Vision: To be the World Leader in the

bioanalytical testing market

Our Mission:To contribute to global health andsafety by providing our customers with high

quality laboratory and advisory services whilstcreating opportunities for our employees andgenerating sustainable shareholder value

Our Values:Achievement of our Mission is

based on Eurofins "Core Values", whichcommit us to Customer focus, Quality,Competence & Team Spirit and Integrity

Revenues in m CAGR16%

2008 2009 2010 2011 2012

EBITDA in mCAGR

20%

2007 2008 2009 2011 2012* Objective

Eurofins shares are listed on

NYSE Euron ext Paris(since IPO in Octo ber 1997)

ISIN FR0000038259, Reuters EUFI.PA,Bloomberg ERF FPIndices: SBF120, Next 150, Next Biotech, SRD,Compartment A

Share price performance as of 26 July 2013(158.5) vs. IPO (10/1997 at 1.83) +8,556%(32% CAGR)

Contact andAddresses

Florian Heupel, Group Marketing

info@eurofins.com10A, Rue Henri M. Schnadt, L-2530,LuxembourgTel +352 261 85 31

Pamela Antay, Investor Relationsir@eurofins.comChausse de Malines 455B- 1950 Kraainem (Brussels)BelgiumTel +32 2 766 1620

Please refer to our on-line group directory forlaboratory contact informationhttp://www.eurofins.com/media/7854659/group_directory_march_2013.pdf

EUROFINS FACT SHEET

Company OverviewEurofins Scientific is an international life sciences company which provides a unique rangeof analytical testing services to clients across multiple industries. The Group is the worldleader in food and pharmaceutical products testing. It is also number one in the world in thefield of environmental laboratory services and discovery pharmacology, and one of theglobal market leaders in agroscience, genomics and central laboratory services.

Short HistoryEurofins Scientific was founded in 1987 with 10 employees to market the SNIF-NMRtechnology, a patented analytical method used to verify the origin and purity of severaltypes of food and beverages and identify sophisticated fraud not detectable by othermethods.

Today the Eurofins Group is a leading provider of analytical services with:

an international network of around 180laboratories across 35countries in Europe,the USA, Asia-Pacific and South America

over 14,000staff

a portfolio of over 100,000reliable and validated analytical methods

more than 80 millionassays performed each year to establish the safety, identity,composition, authenticity, origin, traceability, and purity of biological substances andproducts.

Eurofins is one of the fastest growing companies in Europe. Since its IPO on the Frenchstock exchange in 1997, Eurofins sales have increased by over 40% each year (incompound average) to EUR 1.04 billion in 2012.

Between the Initial Public Offering on 24 October 1997 and 26 July 2013, Eurofins shareprice has multiplied by 87x, an annual average increase of 32% (against 3% for the SBF120, 2% for the CAC 40 and 6% for the Nasdaq over the same period).

Recent DevelopmentsIn 2012, Eurofins exceeded by almost 5% its EUR 1 billion revenue objective a full yearahead of schedule. The early achievement of this objective reflects the benefits of bothpast and ongoing investments to ensure the most comprehensive portfolio of analyticalmethods and the most robust, state-of-the-art laboratory network that allows the Group toprovide the best analytical service to the markets it serves in the most efficient manner.Having consistently invested more than any of its peers in the testing industry, Eurofinsboasts a very modern, streamlined network of laboratories uniquely capable of providinghigh quality analyses at a reasonable cost.

In the 25 years since its foundation, Eurofins has embarked on two intense investmentphases. The first cycle (2000-2004) saw Eurofins expand its technological portfolio andsecure market leadership in Europe; the second cycle (2006-2010) expanded the Groupsgeographical footprint and established the Group as the global reference in laboratorytesting of food, the environment and pharmaceutical products. Investments in start ups in15 new countries, along with focused acquisitions, have substantially increased the rangeof Eurofins offerings in its customers key markets around the world. Overall, thelaboratories started up by Eurofins in the last six years in new markets such as India,China, Brazil, Singapore and Eastern Europe provide an increasingly important growthengine for the Group.

Over the years, Eurofins has developed many new analytical testing methods and has

participated in, or led several R&D projects to find better ways to analyse food, theenvironment and pharmaceuticals. Drawing on its world-class Competence Centres andits expertise, Eurofins is driving growth from its market-leading portfolio of tests,outsourcing agreements and through cross-selling opportunities across its world-widelaboratory network.

Future PlansEurofins is committed to supporting its clients objectives of ensuring that their productsreach the best possible quality and safety levels in all markets in which they operate. TheGroup intends to continue to develop and acquire the most comprehensive range of state-of-the-art analytical technologies as well as expand its geographical reach in order tosupport its clients increasingly stringent quality and safety standards and the expandingdemands of regulatory authorities around the world.

Eurofins has set an objective of doubling in size over the next five years to reach EUR 2bnin revenues by 2017. Over this period, Eurofins plans to spend about EUR 500m in themost modern laboratory network, analytical technology and IT systems to offer its clientsan ever expanding unmatched range of innovative, reliable and cost-effective testingservices.

80 59

93

139

161

1,044

633640

680

829

2,000

2017*

mailto:info@eurofins.commailto:info@eurofins.commailto:ir@eurofins.commailto:ir@eurofins.comhttp://www.eurofins.com/media/7854659/group_directory_march_2013.pdfhttp://www.eurofins.com/media/7854659/group_directory_march_2013.pdfhttp://www.eurofins.com/media/7854659/group_directory_march_2013.pdfhttp://www.eurofins.com/media/7854659/group_directory_march_2013.pdfhttp://www.eurofins.com/media/7854659/group_directory_march_2013.pdfmailto:ir@eurofins.commailto:info@eurofins.com